Cost Is the Biggest Barrier to Ketamine Adherence — Here's How Providers Can Help

You've seen the clinical data. You've seen the patient outcomes. Ketamine — whether administered as IV infusions, compounded oral formulations, or Spravato (Esketamine) nasal spray — can be transformative for patients with treatment-resistant depression, chronic pain, PTSD, and other conditions that haven't responded to conventional therapies.

But there's a problem that clinical trials don't solve: most patients can't afford it.

Off-label IV Ketamine infusions typically cost $400–$800 per session, with an initial course of 6 sessions running $2,400–$4,800 out of pocket. Spravato sessions run $800–$1,200 without insurance. Even compounded at-home formulations through telehealth programs cost $150–$400 per month. For patients already burdened by the costs of managing complex conditions, these numbers can be prohibitive.

As a prescriber, you're uniquely positioned to help patients navigate these costs — and in doing so, improve adherence, outcomes, and the patient-provider relationship. This guide covers the savings programs and strategies available.

What Your Patients Are Actually Paying

Understanding the cost landscape helps you counsel patients realistically:

IV Ketamine Infusions

• Per session: $400–$800
• Initial course (6 sessions): $2,400–$4,800
• Maintenance (monthly): $400–$800
• Insurance coverage: Almost never covered for off-label depression use

IM Ketamine Injections

• Per session: $300–$600
• Insurance coverage: Rarely covered for off-label use

Spravato (Esketamine) Nasal Spray

• Per session: $800–$1,200 without insurance
• With insurance: Often covered with prior authorization; patient copay varies
• Savings program: Janssen Spravato Savings Program can reduce copays to as low as $10/session

Compounded Oral/Sublingual Ketamine

• Per dose: $1–$5 through compounding pharmacies
• Telehealth programs (monthly): $150–$400 (includes consultations)
• Insurance coverage: Almost never covered

Generic Injectable Vials

• Per vial: $12–$50
• Insurance coverage: Typically covered when used for FDA-approved anesthesia indications

Manufacturer Savings Programs

Spravato (Janssen) Savings Program

For patients with commercial insurance, the Janssen Spravato Savings Program is the most impactful cost-reduction tool available. Key details:

• Eligible commercially insured patients can pay as low as $10 per treatment session
• Covers the difference between the patient's copay and the program benefit
• Enrollment is available through the Spravato REMS portal or by calling Janssen CarePath
• Not available for patients on government insurance (Medicare, Medicaid, Tricare, VA)

For practices that prescribe Spravato, proactively enrolling eligible patients in this program should be standard workflow. The enrollment process takes minutes and can save patients hundreds per session.

Generic Ketamine — No Manufacturer Program

Because generic Ketamine is manufactured by multiple companies (Hikma, Eugia, Fresenius Kabi, AuroMedics, Par Pharmaceutical), there is no manufacturer savings program. Cost management for generic Ketamine relies on other strategies outlined below.

Coupon and Discount Cards

For patients filling generic Ketamine prescriptions at retail pharmacies, discount cards can provide modest savings:

• GoodRx — May show pricing for Ketamine vials at retail pharmacies; savings vary by location
• SingleCare — Check for pharmacy-specific pricing
• RxSaver — Compare prices across local pharmacies

These tools are more helpful for the injectable vial cost than for infusion clinic fees. For compounded formulations, pricing is determined by the compounding pharmacy and is not typically listed on coupon platforms.

For a comprehensive list of coupon resources to share with patients, see the patient-facing guide on saving money on Ketamine.

Patient Assistance Programs

For uninsured or underinsured patients who cannot afford treatment:

Janssen CarePath (Spravato)

Janssen offers patient assistance for Spravato for patients who are uninsured or underinsured and meet financial eligibility criteria. This can provide Spravato at no cost to qualifying patients.

NeedyMeds

NeedyMeds maintains a database of copay assistance and patient assistance programs. Search for Ketamine or Esketamine to find current programs.

RxAssist and RxHope

These databases aggregate patient assistance programs from multiple sources and can help identify options for patients facing financial hardship.

Clinic-Level Programs

Many Ketamine infusion clinics offer their own financial assistance:

• Sliding-scale pricing based on income
• Payment plans that spread the cost of an initial 6-session course over several months
• Package discounts for purchasing multiple sessions upfront
• Reduced rates for patients who have exhausted other options

If your practice offers Ketamine infusions, consider implementing at least one of these options. Even a modest payment plan can make the difference between a patient starting treatment and walking away.

Generic Alternatives and Therapeutic Substitution

When discussing Ketamine with patients, it's worth considering the full range of treatment options along the cost spectrum:

Route of Administration Matters for Cost

The same molecule at vastly different price points:

• IV infusions ($400–$800/session) — Most studied, rapid onset, but most expensive
• IM injections ($300–$600/session) — Slightly less expensive, still requires clinical setting
• Compounded oral lozenges ($1–$5/dose) — Dramatically less expensive per dose, suitable for at-home maintenance after initial in-clinic stabilization
• Telehealth programs ($150–$400/month) — Mid-range cost, includes prescriber supervision

A common cost-effective protocol: start patients with an in-clinic IV or IM series for rapid stabilization, then transition to compounded oral Ketamine for maintenance. This approach balances clinical effectiveness with long-term affordability.

Spravato vs. Generic Ketamine: Insurance Considerations

For patients with commercial insurance, Spravato may actually be less expensive than IV Ketamine once insurance coverage and the Janssen savings program are factored in. Run the numbers with your patient:

• Spravato with commercial insurance + savings card: potentially $10–$50/session
• IV Ketamine without insurance: $400–$800/session

The trade-off: Spravato requires REMS certification and in-office administration with 2-hour monitoring, which has workflow implications for your practice. But for the patient's wallet, it can be the more affordable option.

Alternative NMDA-Modulating Medications

For patients who cannot access or afford Ketamine in any form, consider:

• Dextromethorphan/Bupropion (Auvelity) — FDA-approved for MDD, works partly through NMDA modulation, oral pill, may have insurance coverage

For a broader discussion of alternatives, see the patient guide on alternatives to Ketamine.

Building Cost Conversations Into Your Workflow

Cost discussions shouldn't be an afterthought. Here's how to integrate them into your clinical practice:

During the Initial Consultation

• Present all route-of-administration options with their approximate costs
• Ask about insurance coverage and financial constraints upfront
• Check Spravato insurance eligibility before the patient leaves the office
• Provide printed or digital information about savings programs

At the Treatment Decision Point

• If recommending IV/IM infusions, discuss the total cost of the initial course (not just per-session)
• Offer payment plans or package pricing if available
• For Spravato, enroll in the Janssen Savings Program during the same visit
• For compounded formulations, recommend specific compounding pharmacies with transparent pricing

During Ongoing Treatment

• Reassess the route of administration as the patient stabilizes — can you transition to a less expensive maintenance option?
• Check in on financial burden periodically — patients may not volunteer that they're struggling to afford sessions
• Help patients find Ketamine when shortages occur — Medfinder for Providers can help locate pharmacies with availability

Staff Training

Your front office and clinical staff should be familiar with:

• The Spravato Savings Program enrollment process
• Your practice's payment plan options
• How to direct patients to NeedyMeds, RxAssist, and other assistance resources
• Where to find current Ketamine shortage updates for providers

Final Thoughts

The clinical promise of Ketamine means nothing if patients can't afford to access it. As the provider landscape for Ketamine treatment continues to grow, practices that proactively address cost barriers will see better adherence, better outcomes, and more satisfied patients.

The tools exist — manufacturer savings programs, patient assistance, flexible dosing routes, payment plans, and insurance navigation for Spravato. The challenge is building them into your workflow so that every patient hears about their options before cost becomes a reason to stop treatment.

Need help locating Ketamine for your patients? Visit Medfinder for Providers to check real-time pharmacy availability and help your patients find medications in stock.